Leqembi And Skyclarys Expected To Drive Biogen's Future Growth: Analysts

On Wednesday, Biogen Inc BIIB reported fourth-quarter adjusted EPS of $3.44, up 17%, beating the consensus of$ 3.35.The company reported sales of $2.46 billion, up 2% year over year on constant currency and 3% on a reported basis, beating the consensus of$ 2.40 billion.Needham analyst Ami Fadia expects challenges in the multiple sclerosis segment, as growth from key product launches isn’t enough to make up for declines.While Leqembi sales performed well outside the U.S. and Skyclarys is set to grow internat ...